(2E)-1-(2,4-difluorophenyl)-3-(dimethylamino)prop-2-en-1-one | 1221502-97-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2E)-1-(2,4-difluorophenyl)-3-(dimethylamino)prop-2-en-1-one
• 英文别名: (E)-3-(dimethylamino)-1-(2,4-difluorophenyl)prop-2-en-1-one；1-(2,4-Difluorophenyl)-3-(dimethylamino)prop-2-en-1-one；(E)-1-(2,4-difluorophenyl)-3-(dimethylamino)prop-2-en-1-one
• CAS: 1221502-97-1
• 化学式: C₁₁H₁₁F₂NO
• 分子量: 211.211
• InChiKey: ODGKAPMOYVGPNZ-AATRIKPKSA-N

物化性质

• 沸点：
  275.7±40.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)
• 溶解度：
  >31.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2E)-1-(2,4-difluorophenyl)-3-(dimethylamino)prop-2-en-1-one 在 ferrous(II) sulfate heptahydrate 、 硫酸 、 双氧水 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 4-(2,4-difluorophenyl)pyrimidine-2-carboxamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

  摘要：

  Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC50] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.019
• 作为产物：
  描述：

  2',4'-二氟苯乙酮 、 N,N-二甲基甲酰胺 以 二甲胺 为溶剂， 以81%的产率得到(2E)-1-(2,4-difluorophenyl)-3-(dimethylamino)prop-2-en-1-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

  摘要：

  Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC50] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.019

文献信息

• PYRAZOLE COMPOUNDS
  申请人：FUKUMOTO Shoji

  公开号：US20100094000A1

  公开（公告）日：2010-04-15

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.

  本发明涉及其中每个符号如规范中定义的。该化合物具有优越的矿物皮质激素受体拮抗作用，并可用作通过矿物皮质激素受体激活介导的疾病或病况的预防或治疗剂。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014089364A1

  公开（公告）日：2014-06-12

  Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本文提供了替代嘧啶基吡唑啉、嘧啶基吡唑啉和嘧啶基吡咪啉衍生物化合物以及包含这些化合物的药物组合物。这些化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，这些化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等癌症有用。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US20140194469A1

  公开（公告）日：2014-07-10

  Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本文提供了代替的吡唑基吡啶、吡唑基吡嗪和吡唑基嘧啶衍生物化合物及包含该化合物的药物组合物。该化合物和组合物可用于抑制组蛋白去甲基化酶。此外，该化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Histone demethylase inhibitors
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US08987461B2

  公开（公告）日：2015-03-24

  Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本文提供了取代的吡唑基吡啶、吡唑基吡嗪和吡唑基嘧啶衍生物化合物以及包含该化合物的药物组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，该化合物和组合物对于治疗癌症，例如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用途。
• PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS
  申请人：Celgene Quanticel Research, Inc.

  公开号：EP3763367A1

  公开（公告）日：2021-01-13

  Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本文提供了取代的吡唑基吡啶、吡唑基哒嗪和吡唑基嘧啶衍生物化合物以及包含上述化合物的药物组合物。上述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物还可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。